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Background
Despite 20 years of effort, the design of an effective HIV-1
vaccine remains an enormous challenge. In this scenario,
new immunological approaches must be considered.
Dendritic cells-based vaccines have been widely used in
cancer therapy showing interesting successful results.
More recently, Lu et al. (2004) described large reductions
on virus load in untreated HIV-infected patients immu-
nized with autologous DC pulsed with inactivated viruses.
Although encouraging, these results showed sustained
virus reduction in only half of vaccinees. Besides, isolating
virus from each patient is a rather laborious and expensive
process. Based on that monocyte-derived dendritic cell
(Mo-DC) vaccine model we evaluated the use of alterna-
tive HIV products in order to simplify the process of vac-
cine production, reduce costs and achieve protective
immune responses on a greater number of individuals.
Methods
Monocytes from HIV-serodiscordant couples were differ-
entiated in vitro into dendritic cells, pulsed with a pool of
aldrithiol-2-inactivated HIV-1 subtypes or the HIV-1IIIB
p55Gag protein and then cultured with autologous lym-
phocytes for 7 days. At day 7, the culture received a boost
of fresh Mo-DCs pulsed with the same antigens. The T
lymphocyte immunological response was determined by
proliferation assay, IFNγ production and cellular activa-
tion. The Mo-DC phenotype was also evaluated.
Results
Mo-DCs were shown to be fully matured and activated
(CD11c+HLA-DRhiCD86hiCD80hiCD83+) in both anti-
gen-pulsing protocols. IFNγ production by T CD4+ and
CD8+ lymphocytes, as well as the percentage of CD38+
cells, was always higher when stimulated with pulsed Mo-
DCs compared to non-pulsed cells. The T lymphocyte pro-
liferation of pulsed Mo-DCs was also significant greater
compared to the non-pulsed condition, being slightly but
not significantly higher in p55Gag-pulsed cells.
Conclusion
This easier and cheaper Mo-DC vaccine model elicited in
vitro detectable cellular immune responses in HIV-unin-
fected subjects, which suggests a broader range of action
and represents a viable and promising alternative of ther-
apeutic vaccination.
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